Why the study?
Does aspirin reduce the incidence of cardiovascular disease in primary and secondary prevention populations?
Does aspirin reduce the incidence of cardiovascular disease in primary and secondary prevention populations?
Aspirin is reviewed for its efficacy in primary and secondary prevention of cardiovascular disease, with observational data suggesting a 20% reduction in incidence, though large randomized trials are needed for reliable assessment.
Answers are grounded in this paper and cite their sources.
Should not change aspirin prescribing in CVD prevention; leaves open efficacy pending large randomized trials.
A ntiplatelet therapy, particularly with aspirin, has become the focus of much research in the treatment and prevention of cardiovascular disease.In this paper, we review the evidence of efficacy; first, for patients who have a history of myocardial infarction (M1), stroke, tran- sient cerebral ischemia (TCI), or unstable angina; second, for those actually undergoing acute myo- cardial infarction (AMI); and, finally, for appar- ently healthy individuals.Mechanism of Action of Aspinin Aspirin permanently inhibits cyclooxygenasedependent platelet aggregation.1-8Even low dose aspirin (e.g., 80 mg/day) will, within a few days, inhibit platelet cyclooxygenase so completely that little further effect on this mechanism of platelet aggregation would be expected at higher daily doses of the drug,3'6'8 although, if antiplatelet therapy is to be started during an acute vascular event, such as MI, then a somewhat higher loading dose (at least 160 mg) might be preferred to ensure a rapid antithrombotic effect.During the past 20 years, there have been reports from observational epidemiologic studies of aspirin as well as a number of randomized trials.Taken as a whole, the case-control and cohort studies suggest that aspirin may reduce the incidence of cardiovas- cular disease by about 20%,9-12 which, if true, would be clinically worthwhile and would have an important impact on public health.Unfortunately, however, the amount of uncontrolled confounding inherent in such observational studies could be about as great as the postulated benefit.13In gen- eral, reliable assessment of such modest benefits can be derived only from large randomized trials.
No takes yet. Share an insight, caveat, or question.
Hennekens et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: